|
| | Median (IQR)/count (frequency, %) |
|
| Age, years | 56 (48–61) |
| Men, (%) | 29 (66) |
| Deceased-donor KT, (%) | 41 (93) |
| Previous transplants: 0/1/2, (%) | 36/4/4 (82/9/9) |
| Dialysis prior to KT, (%) | 42 (96) |
| Time on dialysis prior to KT, years | 3.2 (2.4–4.3) |
| Time between first renal replacement therapy until inclusion, years | 6.0 (4.5–10.3) |
| Time between last KT and development of hypercalcemia, months | 1.0 (0.5–2.1) |
| Time between last KT and cinacalcet initiation, years | 1.8 (0.8–4.7) |
| Laboratory findings, unit (reference range) | |
| Estimated glomerular filtration rate, mL/min/1.73 m2 | 51.2 (43.5–57.8) |
| Total serum calcium, mmol/L (2.10–2.60) | 2.77 (2.68–2.84) |
| Fractional calcium excretion, % (1-2) | 0.77 (0.44–1.45) |
| Serum inorganic phosphate, mmol/L (0.81–1.45) | 0.79 (0.72–0.89) |
| TmP/GFR, mmol/L (0.80–1.40) | 0.54 (0.46–0.63) |
| Intact parathyroid hormone, pg/mL | 156 (112–236) |
| Bone specific alkaline phosphatase, ng/mL (5.2–24.6) | 23.1 (16.8–32.9) |
| Osteocalcin, ng/mL (15–35) | 54.6 (37.7–91.8) |
| C-telopeptide, ng/mL (0.08–0.44) | 0.65 (0.43–1.02) |
| Native kidney disease, (%) | |
| Polycystic disease | 12 27.3 |
| Glomerular disease | 11 25.0 |
| Vascular disease | 3 6.8 |
| Diabetes mellitus | 2 4.5 |
| Others | 7 15.9 |
| Unknown | 9 20.5 |
| Immunosuppressive therapy, (%) | |
| Cyclosporine A/tacrolimus | 17/22 (38.6/50.0) |
| Mycophenolate mofetil/azathioprine/leflunomide | 40/1/1 (90.9/2.3/2.3) |
| Sirolimus/everolimus | 1/1 (2.3/2.3) |
| Belatacept | 2 4.5 |
| Steroids | 40 90.9 |
| Pretransplant use of cinacalcet, (%) | 13 29.5 |
|
